The majority of infections acquired during adulthood are resolved without intervention; however, infections acquired at birth or during early childhood have a 90% chance of progressing to CHB, leading to a host of adverse effects on the liver, including cirrhosis and cancer. CHB is currently treated with a combination of cytokines and/or nucleoside/nucleotide analogues; however, adverse side effects to cytokine therapy and the selection of resistance mutations to nucleoside analogues often abrogate the efficacy of treatment. The recent discovery that small interfering RNA and microRNA are active in mammalian cells suggests it might be possible to supplement existing HBV therapies with small RNA-based therapeutic(s).
Hepatitis B virus (HBV) infection is a global human health problem, with an estimated 350 million people having chronic hepatitis B (CHB) infection worldwide.
The majority of infections acquired during adulthood are resolved without intervention; however, infections acquired at birth or during early childhood have a 90% chance of progressing to CHB, leading to a host of adverse effects on the liver, including cirrhosis and cancer. CHB is currently treated with a combination of cytokines and/or nucleoside/nucleotide analogues; however, adverse side effects to cytokine therapy and the selection of resistance mutations to nucleoside analogues often abrogate the efficacy of treatment. The recent discovery that small interfering RNA and microRNA are active in mammalian cells suggests it might be possible to supplement existing HBV therapies with small RNA-based therapeutic(s).
It is estimated that as many as 2 billion people have been infected with hepatitis B virus (HBV) [1] and over 1 million people die each year from HBV-related diseases [2] . Although 95% of people infected during adulthood spontaneously clear the virus, over 90% of perinatal infections progress to chronic hepatitis B (CHB) infection [3] , affecting approximately 387 million people worldwide [4] . HBV is an oncogenic virus [5] and individuals who have had CHB for greater than 30 years have a 200-fold higher risk of developing hepatocellular carcinoma (HCC) relative to the general population [6] . HCC accounts for between 80% and 90% of liver cancers [7] and CHB places a huge burden on public health resources, especially in African and Asian countries where it is endemic.
Although an effective preventative vaccine is available, current therapies are largely unsatisfactory because of the emergence of antiviral-resistant HBV or adverse side effects. There is an urgent need for the development of new approaches to combat this global health problem. Recent advancements in the understanding of RNA interference (RNAi) could result in new tools suitable for the development of effective anti-HBV therapies.
HBV structural biology and replication
HBV is a relatively small, generally non-cytopathic, partially double-stranded DNA virus encoding a 3.2 kb genome, present as a relaxed circular DNA (rcDNA) form in virions [3] . After viral entry into the host cell, rcDNA is converted into a covalently closed circular DNA (cccDNA), which is located in the nucleus in the form of a minichromosome (reviewed by [8] ). The genome is highly compact with four overlapping open reading frames and overlapping regulatory sequences. The cccDNA serves as the template for the transcription of both greater-than-genome-length and subgenomic RNAs. Five sets of messenger RNAs (mRNAs) are transcribed from the viral minichromosomes and transported to the cell cytoplasm, using a virally encoded post-transcriptional regulatory element that interacts with cellular RNA binding proteins involved in HBV mRNA export and stability [9] . The mRNAs are coterminal and encode the following proteins: the hepatitis B core antigen (or nucleocapsid protein, translated from the 3.6 kb pre genomic greater-than-genome-length RNA [pgRNA]); the polymerase protein (Pol; also translated from the pgRNA); the precore protein, which is processed into In addition to serving as mRNA for the nucleocapsid and Pol, the pgRNA acts as the template for reverse transcription into the viral rcDNA genome, which occurs within the viral nucleocapsid. The pgRNA encodes an encapsidation signal (ε), which permits packaging of the RNA into viral nucleocapsids. The presence of nuclear cccDNA presents enormous challenges for therapeutic control of HBV, as cccDNA serves as a constant source of DNA template for the production of viral mRNA and pgRNA.
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Effectiveness of current therapies
Currently, treatment of individuals with CHB is only partially effective, with a limited selection of antiviral drugs available [3] . Anti-HBV drugs fall into two broad categories, cytokines and nucleoside/nucleotide analogues [10] . Cytokines, such as interferon (IFN)-α are immunomodulators that have both antiviral and antiproliferative properties [10] . Robust inhibition of replication can be achieved; however, side effects could be severe and the cost of therapy is prohibitive [10] . For reasons that are unclear, IFN-α therapy is ineffective in >50% of chronically infected patients [10] , and is particularly ineffective in patients who are immunosuppressed or who have higher HBV DNA levels [11] . In addition, the HBV genotypes respond differently to IFN-α, wherein genotype A is more sensitive and faster to respond for reasons that are yet to be elucidated [12, 13] .
Nucleoside/nucleotide analogues lamiviudine (3TC), telbivudine, adefovir, tenofovir and entecavir inhibit the catalytic properties of the reverse transcriptase of HBV by competitive inhibition [13, 14] . However, in order to be effective, the drugs must be taken for long periods, leading to the selection of drug-resistant mutants [9] . Indeed, resistance mutations have been detected after 48 weeks of treatment in studies for all the currently licenced nuceloside/nucleotide analogues [15] , highlighting the urgent need for new therapies to treat the millions of people living with CHB worldwide. For example, after 1 year of 3TC therapy, resistance emerged in 22% of patients, increasing to 69% after 5 years [14] [15] [16] . The HBV resistance mutations that emerge on nucleoside/nucleotide therapy differ for each treatment, emphasizing the need for multidrug therapy and/or new drug targets. The most common mutations conferring 3TC resistance are the rtM204V/I mutations in the YMDD motif of the reverse transcriptase, and the compensatory mutations rtV173L and rtL180M [17] . The rtM204I mutation also confers resistance to telbivudine [18] ; however, these mutants remain sensitive to adefovir [19, 20] , tenofovir [21] and entecavir [19, 22] . Resistance to adefovir is most frequently conferred by the selection of an rtN236T or rtA181V/T mutation in Pol [23] [24] [25] , which might be associated with the development of liver failure [26] . The majority of entecavir resistance mutations occur in patients with 3TC resistance, and 9% of 3TC-resistant patients who are switched to entecavir develop entecavir-resistant mutations after 2 years [17, 27] , increasing to 25% after 3 years [28] . The main additional mutations associated with entecavir resistance in a 3TC-resistant background are rtT184G, rtS202I and rtM250V [28] .
RNA interference
RNA-induced gene silencing mechanisms were initially identified in plants [29] ; however, it was the discovery of specific genetic interference by double-stranded RNA in the nematode Caenorhabditis elegans [30] that heralded interest in the potential for RNAi in human biology and medicine.
RNAi is an evolutionarily conserved mechanism that employs short RNAs in association with an effector complex, referred to as the RNA-induced silencing complex (RISC), to regulate gene expression in a sequencespecific manner [30] . Two classes of small RNAs, which differ in origin and early processing pathways, mediate this process; microRNAs (miRNAs), which are encoded within non-coding regions of cellular or viral RNA transcripts [31] and form imperfect stem loop structures that require nuclear processing before export and maturation in the cytoplasm, and small interfering RNAs (siRNAs), which originate in the cytoplasm and are processed from long stretches of perfectly duplexed coding or non-coding double-stranded RNA.
siRNA processing pathway
In recent years, antiviral research has focused on taking advantage of the RNAi pathway to provide novel treatment approaches. The processing pathways of both miRNAs and siRNAs converge in the cytoplasm and require the activity of three key factors: Dicer, TAR RNA binding protein (TRBP) and Argonaute2 (Ago2). Doublestranded RNA in the cytoplasm, usually produced during viral infection or from transposons, is processed by the RNase III activity of Dicer into approximately 19 base pair duplexes with 3′-dinucleotide overhangs and 5′-phosphates [32] , as summarized in Figure 1 . This duplex then associates with RISC [33] where TRBP recruits Ago2 [34] to facilitate the unwinding of the duplex [35, 36] . The strand with the less tightly basepaired 5′-end [37, 38] is incorporated into RISC and serves as a guide strand for the cleavage of complementary mRNA (Figure 1 ).
miRNA processing pathway
In contrast to cytoplasmic siRNA processing, miRNA biogenesis is a two-stage processing pathway commencing in the nucleus [34] (Figure 1 ), resulting in imperfectly duplexed 22 nucleotide RNAs that regulate target gene expression at the post-transcriptional level [39] . In eukaryotes, miRNAs are endogenously encoded as part of an RNA stem-loop structure of approximately 80 nucleotides, termed primary miRNA (pri-miRNA) [40] . The first stage of miRNA processing occurs in the nucleus and involves cleavage of the pri-miRNA by the RNase III enzyme Drosha in conjunction with its binding partner DGCR8 [41] , forming pre-miRNA, an RNA hairpin of approximately 65 nucleotides, with two nucleotide 3′ overhangs [41, 42] . Pre-miRNAs are exported to the cytoplasm by Exportin-5 [43] , which also functions to stabilize bound miRNAs and to protect them from RNase activity [44] .
Once in the cytoplasm, the second stage of miRNA biogenesis occurs as the pre-miRNA is further processed by Dicer, producing an RNA duplex intermediate of approximately 22 base pairs [45] [46] [47] . The duplex is unwound by Dicer in conjunction with TRBP, and the guide strand is loaded into a RISC by Ago2 to form a miRNA-induced silencing complex [48] . Nucleotides 2-8 of the miRNA are dubbed the seed sequence [49] , and must be perfectly complementary to the 3′-untranslated region of the target mRNA for binding to occur [49] . Each miRNA is capable of regulating multiple mRNA transcripts, playing a vital role in the regulation of cell death, differentiation and development [43, 50] . The precise mechanism by which miRNAs control the expression of proteins is unclear, but miRNAs can suppress protein synthesis either at translation initiation [51] [52] [53] , or translation elongation [54] [55] [56] [57] . miRNA-mediated mRNA decay has also been demonstrated, where miRNAs accelerate decay by recruiting components of the general mRNA degradation machinery [58, 59] . miRNA-mediated mRNA degradation requires an Ago protein, the P-body component GW182, the CCR4-CAF1-NOT deadenylase complex, the decapping enzyme DCP2 and several other decapping activators [48, 60, 61] . Several of these degradation mediators are components of cytoplasmic processing bodies (P bodies), which have also been implicated in the miRNA-mediated regulation of mRNA by sequestrating target mRNA [62] , although this sequestration might be a consequence of regulation, rather than the cause [54, 63, 64] .
RNAi for the control of viral pathogens
RNAi has been used to inhibit the replication of several pathogenic viruses in culture, including respiratory syncytial virus [65] , influenza virus [66] , poliovirus [67] hepatitis C [68] and HIV type-1 [69, 70] . HBV represents a promising candidate for RNAi therapy as its small size limits its degree of redundancy, potentially abrogating the issues of resistance encountered in anti-HIV RNAi therapy [71] . In addition, targeting conserved regions in the partially overlapping reading frames will limit the occurrence of compensatory mutations. The use of RNAi to control hepatitis viruses is still in its infancy; however, recent studies in this rapidly expanding field show great promise. Potential targets for anti-HBV siRNA include the pgRNA and subgenomic RNAs, as outlined in Figure 2 .
Successful use of RNAi against HBV
Several methods of anti-HBV siRNA therapy to inhibit HBV replication have been investigated, with some promising results. By targeting multiple sites within an HBV nuclear localization signal (NLS), a 76% reduction in HBeAg levels, a decrease of 70% in HBsAg levels [72] and a 70% reduction in cccDNA [73] was achieved in a cell culture system.
Effective inhibition of HBV replication has also been achieved by targeting the HBsAg and/or the HBeAg in vitro. Using a combination of four siRNA sequences targeting the HBsAg, surface antigen secretion into the cell culture medium was reduced by 61% [74] , a reduction that was dose-dependent. HBV replication has also been inhibited in cell culture using siRNAs targeting the HBx mRNA [75] , which encodes the transactivational X protein required for productive HBV infection in vivo. Because the HBx is not required for productive HBV replication in cell culture [76] , it is likely this effect was mediated by degradation of the overlapping pre-genomic mRNA, which encodes the viral Pol. In addition, siRNAs have been shown to suppress HBsAg and HBeAg secretion by up to 88% in a mouse model [77] . Another successful approach complements the inhibitory effect of siRNAmediated knockdown by also targeting the damagespecific DNA binding protein 1 (DDB1), a transcription factor that modulates HBV transcription [78] . Successful approaches to date have included both single-and multi-panel targets [79, 80] (Table 1) .
Although the inhibition achieved by many of these approaches is promising, the issue of how to improve the inhibitory effect of RNAi remains a challenge. Longterm suppression of HBV replication has been achieved using a scaffold/matrix attachment region-based replicating vector system approach, in which HBV replication was inhibited by at least 75% for 8 months in a cell culture system. Most recently, trimeric miRNA shuttle cassettes targeting the HBx mRNA have been used to inhibit HBV replication [81] . This novel approach utilizes a vector that produces three RNAi effectors from a single transcript, thereby enabling the simultaneous knockdown of multiple target sequences. HBV sequences were incorporated into host pre-miRNA backbones downstream of a cytomegalovirus promoter and processed into miRNAs by the endogenous Drosha and Dicer pathways. In luciferase-driven reporter assays, these constructs effectively silenced HBV target sequences and, importantly, HBV replication was also silenced in a mouse model. This multi-effector approach silenced HBV-driven luciferase reporter expression, even when the HBV target harboured a mutation. Importantly, Ely et al. [81] showed that this trimeric approach did not disrupt endogenous miRNA pathways, nor did it result in stimulation of the innate IFN response, both important considerations for any RNAi-driven therapy.
A major consideration for employing RNAi against HBV is the nuclear pool of cccDNA, which is not directly targeted by siRNA or miRNA. cccDNA is the major transcriptional template for both pgRNA and viral mRNAs and its presence in the nucleus ensures a continual supply of HBV replication intermediates. Although numerous RNAi studies have shown substantial reductions in HBV replication by targeting cytoplasmic viral mRNAs, cccDNA is largely unaffected by this approach. A recent study by Li et al. [72] shows it might be possible to reduce cccDNA indirectly, by targeting an HBV-encoded NLS, thereby reducing the amount of HBV DNA that is transported to the nucleus; however, the elimination of nuclear cccDNA remains the ultimate goal for current and future HBV therapies.
Delivery of small RNAs
Early experiments on HBV gene silencing focused predominantly on chemically synthesized siRNAs to knock down gene expression. More recently, researchers have manipulated the endogenous RNAi pathway itself to silence target genes. By cloning target sequences into a stem loop sequence engineered into a mammalian expression vector, small RNAs targeting the gene of interest are produced following transfection into appropriate cells. This occurs because the stem loop or short hairpin (sh) sequences are effectively analogues of pre-miRNA, and are processed by the endogenous RNAi pathway into miRNA. By comparison, synthetic siRNAs resemble Dicer cleavage products, and cause gene silencing by directly activating RISC. This approach has been used by many groups to knockdown markers of HBV viral replication [82] [83] [84] [85] . Interestingly, many of these studies used vectors encoding Pol III to drive expression of the inserted sequences. It has recently emerged that Pol-IIIdriven expression of shRNAs is cytotoxic in mice because of saturation of the RNAi processing machinery, thereby impairing the ability of the cell to produce miRNAs crucial to its survival [86] . These findings have important implications for the use of shRNA in any future therapy; however, it has recently been shown that Pol-II-driven expression of shRNA sequences are equally effective at silencing HBV gene expression, without saturating the miRNA pathways [87] . The delivery of the relatively high therapeutic doses of siRNAs required is a challenge because of the highly charged nature of the molecules and their nuclease sensitivity. The use of chemically stabilised siRNA [88] , or viral vectors synthesizing siRNA or miRNA, partially addresses these problems [89, 90] . However, unforeseen problems, such as a viral vector-associated death during a gene therapy trial [91] , indicate that issues with immune modulation, toxicity and target accumulation remain unresolved problems. A wide range of non-viral delivery methods have been effective; however, the difficulty might be finding a 'onesize-fits-all' approach to siRNA delivery, especially considering that the delivery technique affects the siRNA uptake by various tissues [92] .
Local and systemic delivery
Proven methods for the local delivery of siRNA generally involve injection directly into a target tissue, thereby reducing unwanted side effects, susceptibility to nucleases and hepatic or renal elimination. For most siRNA applications, however, target organs and tissues are not readily accessible using localized delivery, requiring the use of systemic delivery methods, such as conjugation and delivery vehicles.
Conjugation of siRNAs to lipids or steroids helps the siRNA cross the cell membrane by rendering it more hydrophobic and protecting against nuclease activity by binding to plasma proteins and lipoproteins [93, 94] . This is an attractive method for delivering anti-HBV siRNAs, as the role of the liver in processing lipids and steroids means that these lipid/steroid conjugates will be selectively targeted to hepatocytes [93, 94] . Further methods of conjugation-based delivery include membrane-penetrating peptide (MPP) conjugates, which again assist with entry via the plasma membrane [95] . Disadvantages of MPP conjugates are that siRNA precipitation sometimes occurs with cationic MPPbound siRNAs, the immunogenic properties of siRNAs can be exacerbated, and non-specific knockdown has been observed [96] .
In addition to conjugation-based delivery, lipid-based or cationic macromolecules have also been used successfully. These delivery vehicles are advantageous as they allow controlled release, whether it is the pH-dependent triggered release from liposomes [97] , which has the advantage of protecting the siRNA sequence from degradation and immune recognition, or using fastdegrading polymers as nano carriers [98] . Nano carriers have also been employed by de Martimprey et al. [99] , who successfully delivered siRNAs via chitosancoated poly(isobutylcyanoacrylate) nanoparticles [99] . Other successful methods involve single-chain antibody-mediated delivery, where a nucleic-acid-binding domain is fused to a Fab fragment, creating a fusion protein that binds specifically to the plasma membrane and increases the stability in blood [100] . Using this method, HBsAg levels were decreased over a 10 month period in HepG2.2.15 hepatoma cells [100] .
Targeting siRNA sequences to the liver will obviously be of upmost importance for anti-HBV siRNA therapy. Strategies for targeting to the liver include employing lipid/steroid conjugation (as discussed above), and the Dynamic PolyConjugate system, which actively targets siRNA complexes to hepatocytes, avoiding toxicity and immune stimulation [101] . siRNA has also been successfully targeted to the liver using hydrodynamic injection via the portal vein of mice, a relatively efficient method of delivering high therapeutic doses of siRNA to these animals [102] . Although this approach is a useful animal model for siRNA delivery, applying the hydrodynamic injection technique to humans would be extremely difficult, given the obvious ethical considerations and the complicated balance between systemic toxicity and effective delivery throughout a tissue or organ. Future work using liver-specific promoters to target expression of siRNA/miRNA, as proposed by Ely et al. [87] might overcome many of the problems associated with nonspecific expression of siRNAs, although the delivery of RNAi effectors remains a major challenge.
Immune activation by siRNA
Recognition of siRNA by immunoreceptors including Toll-like receptors (TLRs), protein kinase R and helicases, such as RIG-1 and MDA-5, can trigger a number of cellular responses, including the release of cytokines [103] . A number of factors influence the immunoreceptor involved and the effect of immune activation, including the length and sequence of the RNA, especially GU-rich sequences [104] , as well as the method of siRNA delivery and the immune cell type involved [105] . Chemical modifications to reduce the degree of immune activation involve 2′-O-methylation modifications; however, there is mounting evidence that immune activation of siRNA might actually be beneficial by inducing production of inflammatory cytokines, such as tumour necrosis factor, interleukin (IL)-1 and IL-6, through the TLR7 and TLR8 pathways [106] .
Further complications
Even after successful RNAi delivery and activation, challenges remain. Off-target effects, whereby an siRNA silences an unintended target, are a major concern. These usually occur through partial hybridization with an unintended mRNA, either through the siRNA acting as an miRNA via miRNA-like binding of the seed sequence [107] , or by partial hybridization between the centre of the guide strand and approximately 15 nucleotides from the unintended mRNA. Also, if the passenger strand is incorporated into a RISC, it is capable of acting as a functional miRNA [108, 109] , unintentionally targeting a new set of passenger strandcomplementary mRNAs. To avoid this, the siRNA design can be modified to increase the binding affinity at the 3′-end of the guide strand, to enhance its selection by RISC [110] . Progress has also been made towards increasing the stability of siRNA via chemical modifications of the sugar backbone; however, stability in blood and tissues remains an issue. 2′-O-methylation appears to increase binding affinity and nuclease stability [105] ; however, conflicting results have been reported. There are reports showing a large degree of 2′-O-methylation modification (on either strand) decreases siRNA activity [111] , whereas others suggest that fully modified 2′-Omethylation sense strands remain functional [112] . In addition, 2′-O-methylation modification of the sense strand uridine or uridine/adenosine abrogated the immunostimulatory properties of an anti-HBV siRNA in mice, and indeed, enhances the inhibition of HBV replication [113] . In addition to the binding affinity of the 3′ end, other factors that need to be taken into consideration when designing siRNA/miRNAs to increase their potency include thermodynamic features, guaninecytosine content, secondary structure [114, 115] and the presence of various motifs, including the novel antisense 'UCU' and the antisense 'ACGA' motifs [116] . Designing highly potent RNAi effectors, that is, effectors that effectively silence their target mRNA at low concentrations, is vital, as potent effectors should help overcome issues associated with off-target effects and delivery of sufficient concentrations to target tissues or organs.
Future directions
siRNA-based treatment of HCC
The clinical applications of anti-HBV RNAi are not limited to inhibition of replication, with further applications including the treatment and diagnosis of HCC. The advantages of an siRNA-based anti-cancer therapy is that multiple siRNAs can be delivered simultaneously, enabling both gene silencing and activation of the immune system. Using this multi-siRNA approach, HCC growth and metastasis was reduced in mice with pre-existing liver fibrosis [117] , cancer cell proliferation was inhibited by knockdown of TFIIS, inducing apoptosis [118] and human papillomavirus oncogenes silenced in cervical cancer cells [119] .
A role for small RNAs in diagnosis
The miRNA expression pattern in cancerous tissues has been used as a marker for cancer and to identify the source of a cancer [120, 121] . The most abundant miRNA in the liver, miR122 [122, 123] , is frequently down-regulated in HCC [7, 124] . This down-regulation profile could be used in a diagnostic application, measuring the miRNA expression patterns in HCC, especially the changes in miRNA expression that occur during the development of chronic viral hepatitis and cirrhosis [125] . In addition, miRNA profiling allows associations between oncogene/tumour suppressor mutations and clinical and pathological features to be uncovered [126] .
Immediate challenges
The most important factors that need to be addressed before RNAi is routinely used in antiviral therapies include the elimination of off-target effects and the effective delivery to the target organs. Recent improvements in siRNA design enable siRNAs to distinguish between a single nucleotide [127] [128] [129] , thereby improving sensitivity. In addition, it is vital that siRNAs accumulate at their target tissues and organs without saturating non-intended targets, especially when considering that siRNAs accumulate in the liver and kidneys following systemic administration in mice [130] . It is expected that the use of tissue-or organ-specific promoters, as commonly applied in plant biotechnology, will further this cause.
Conclusions
The potential for developing an anti-HBV siRNA therapeutic is immensely exciting, and the preliminary in vitro results indicate that robust inhibition can be achieved. In addition, any siRNA therapeutic that combines applications of siRNA, for example, targeting both the HBV NLS and DDB1 [78] , will provide even more scope for the clearance of HBV and the cessation of chronic infection. The activity of siRNA is low compared with approved antiviral drugs. However, it is possible that by combining an anti-HBV siRNA therapeutic with more traditional treatments, such as cytokines and nucleoside/nucleotide analogues, a powerful antiviral effect could be achieved. There are several advantages of this tandem approach, including the fact that an effective siRNA therapeutic will reduce viral replication, decreasing the length of treatment, which will limit the selection of compensatory mutations providing resistance to nucleoside/nucleotide analogues. In addition, regulation of immune modulation stimulated by siRNA therapy could enable manipulation of the innate immune response to infection.
Although there remain many issues to be resolved, the advances that have been made in RNAi technologies have been incredibly swift and it is not too optimistic to envisage a time in the foreseeable future where anti-HBV siRNA therapeutics are an effective treatment for individuals with CHB.
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